Covidien plc

Covidien — Merger or Acquisition (July 2014)

24 slides from Covidien's merger presentation, Jul 9, 2014

  1. Slide 1: Town Hall Meeting

    Town Hall Meeting July 9, 2014 Omar Ishrak Chairman and CEO Medtronic, Inc. Filed by Medtronic, Inc. (SEC File No.: 001-07707) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Covidien plc SEC Fi

  2. Slide 2: Medtronic to Acquire Covidien

    Medtronic to Acquire Covidien Creates the premier global medical technology and services company with unmatched breadth and patient reach

  3. Slide 3: Agenda

    Agenda Strategic Fit Combined Impact COVIDIEN About Medtronic Integration Guidelines Q&A

  4. Slide 4: About Medtronic

    About Medtronic

  5. Slide 5: Fulfilling Unmet Medical Needs

    Fulfilling Unmet Medical Needs

  6. Slide 6: The Medtronic Mission: A Shared Sense of Purpose

    The Medtronic Mission: A Shared Sense of Purpose To contribute to human welfare…alleviate pain, restore health, and extend life… To direct our growth in the areas of maximum strength and ability… To strive without reserve for the greatest reliability and quality… to be recognized as a company of ded

  7. Slide 7: Universal Healthcare Needs

    Improve Clinical Outcomes Expand Access Optimize Cost and Efficiency Universal Healthcare Needs

  8. Slide 8: Strategies to Address Healthcare Needs

    Economic Value Globalization Strategies Therapy Innovation Universal HC needs Improve clinical outcomes Expand access Optimize cost and efficiency Strategies to Address Healthcare Needs

  9. Slide 9: Three Business Groups Address Broad Spectrum of Diseases

    Three Business Groups Address Broad Spectrum of Diseases The data in this chart has been intentionally rounded to the nearest whole percentage and therefore does not sum to 100%. Cardiac Rhythm Disease Management 30% Coronary 11% Structural Heart 7% Endovascular Therapies 5% Diabetes 9% Surgical Tec

  10. Slide 10: Strategic Fit

    Strategic Fit

  11. Slide 11: Combination Results in Strategic Diversification

    Combination Results in Strategic Diversification Restorative Therapies Group Spine Neuromodulation Surgical Technologies Cardiac and Vascular Group Cardiac Rhythm Structural Heart Coronary Vascular Endovascular Diabetes Group Surgical Solutions Respiratory & Patient Care Vascular Therapies Restorati

  12. Slide 12: A Strong Strategic Fit

    Delivering strong launch cadence of meaningful therapies and procedures Addressing the inequities in healthcare access globally Becoming a leader in value-based healthcare by incorporating EV into our DNA & Uniquely positioned to expand our industry- leading franchises through our three differentiat

  13. Slide 13: Three Key Benefits for Medtronic and Covidien

    Three Key Benefits for Medtronic and Covidien Therapy Innovation Therapy Innovation 1. Strengthen and enhance Peripheral Vascular and Neuroscience portfolios 2. Leverage adjacencies in Medtronic Surgical Technologies and Covidien Surgical Solutions 3. Accelerate market adoption of early stage Covidi

  14. Slide 14: Combined Company Immediately Accelerates Ability to Expand Global Access

    Combined Company Immediately Accelerates Ability to Expand Global Access countries 150 + locations 300 + combined EM revenue $3.7B Covidien products such as surgical tools and capital equipment are adopted earlier in hospitals, becoming a base for Medtronic chronic disease therapies Combined R&D and

  15. Slide 15: A Robust and Unmatched Integrated Health Solutions Partner

    A Robust and Unmatched Integrated Health Solutions Partner Diagnostic, Surgical, and Critical Care Technologies Value primarily realized in hospital efficiency Chronic Disease Therapies Value primarily realized in post-acute setting Economic Value COVIDIEN

  16. Slide 16: Integration Guidelines

    Integration Guidelines

  17. Slide 17: Guiding Principles for Integration

    Guiding Principles for Integration • Continue to act as independent companies until transaction close • Keep focus and protect current business momentum in our respective companies • Plan for integration now to be ready for Day 1 post-close • Focus on creating lasting value beyond stated cost synerg

  18. Slide 18: Integration Team Structure

    Integration Team Structure Medtronic Medtronic Geoff Martha Bill Burke Medtronic Steering Committee Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Cross-functional teams Commercial teams Functional teams Med

  19. Slide 19: Combined Impact

    Combined Impact

  20. Slide 20: Transforming Healthcare Around the World to Improve More Lives Together

    Transforming Healthcare Around the World to Improve More Lives Together: Every seconds $27 Billion Healthcare Leader 87,000+ Employees Life-Changing Impact for Millions of Patients

  21. Slide 21: Q&A

    Q&A

  22. Slide 22: No Offer or Solicitation

    NO OFFER OR SOLICITATION This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the

  23. Slide 23: Cautionary Statement Regarding Forward-Looking Statements

    Cautionary Statement Regarding Forward-Looking Statements Statements contained in this communication that refer to New Medtronic’s, Medtronic's and/or Covidien’s estimated or anticipated future results, including estimated synergies, or other non-historical facts are forward-looking statements that

  24. Slide 24: Town Hall Meeting

    Town Hall Meeting Omar Ishrak Chairman and CEO Medtronic, Inc.

Covidien — Merger or Acquisition (July 2014) on 6ix